EcoDrugPlus

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSSPAG00000013039
Gene Symbol: LOC103359167
2 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSSPAG00000009030
Gene Symbol: LOC103374742
2 Cross references
178 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSSPAG00000014640
Gene Symbol: LOC103361844
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-5 Subunit

Ensembl ID : ENSSPAG00000014925
Gene Symbol: LOC103369746
3 Cross references
184 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSSPAG00000014238
Gene Symbol: LOC103370321
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSSPAG00000014277
Gene Symbol: LOC103370323
3 Cross references
184 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSSPAG00000021328
Gene Symbol: LOC103365348
3 Cross references
224 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSSPAG00000009047
Gene Symbol: XDH
3 Cross references
208 Possible Orthologues:

Ensembl ID : ENSSPAG00000023486
Gene Symbol: -
Cross references: -
232 Possible Orthologues:

Ensembl ID : ENSSPAG00000007678
Gene Symbol: -
Cross references: -
146 Possible Orthologues:

Ensembl ID : ENSSPAG00000018020
Gene Symbol: -
Cross references: -
220 Possible Orthologues:

Ensembl ID : ENSSPAG00000018496
Gene Symbol: -
Cross references: -
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).